Valuation: Structure Therapeutics Inc.

Market Cap 3.53B 3.08B 2.84B 2.61B 4.95B 339B 5.04B 33.96B 13.32B 166B 13.24B 12.95B 572B P/E 2026 *
-34.7x
P/E 2027 * -23.9x
Enterprise Value 2.45B 2.15B 1.98B 1.82B 3.45B 236B 3.51B 23.63B 9.27B 115B 9.22B 9.01B 398B EV / Sales 2026 *
63.8x
EV / Sales 2027 * 66,884x
Free-Float
76.06%
Yield 2026 *
-
Yield 2027 * -
1 day-1.92%
1 week-9.60%
Current month-7.55%
1 month+15.21%
3 months-8.53%
6 months-41.64%
Current year-28.66%
1 week 48.1
Extreme 48.1
54.99
1 month 42.79
Extreme 42.79
57.07
Current year 35.78
Extreme 35.78
94.77
1 year 15.8
Extreme 15.8
94.9
3 years 13.22
Extreme 13.22
94.9
5 years 13.22
Extreme 13.22
94.9
10 years 13.22
Extreme 13.22
94.9
Manager TitleAgeSince
Director of Finance/CFO 48 2022-04-30
Chief Executive Officer 62 2019-04-30
Chief Operating Officer 49 2026-04-14
Director TitleAgeSince
Director/Board Member 62 2019-01-31
Chairman 68 2022-01-18
Director/Board Member 66 2022-03-28
Date Insider Type Main position Quantity % Market Cap.
06-24Fiscal year

Chief Technology Officer

86,658 0.0620%
06-16Free

Director

39,453 0.0282%
06-16Free

Director

39,453 0.0282%
Change 5-day change 1-year change 3-year change Capi.($)
-1.92%-9.60%+158.03%+47.24% 3.53B
+3.13%+13.95%+64.21%+94.35% 57.82B
-1.39%-6.15%+56.05%+124.73% 53.71B
-0.27%-5.77%+6.75%+433.06% 23.8B
+1.76%-1.65%-16.86%-15.01% 23.26B
+1.47%+8.31%+47.57%-1.74% 20.7B
+1.94%+0.21%+39.31%-27.77% 17.81B
+10.00%-4.30%+208.33%+370.99% 16.9B
-1.77%+10.74%+48.00%+704.90% 16.36B
-0.39%-1.00%+26.08%+186.49% 13.96B
Average +1.24%+0.31%+63.75%+191.72% 24.79B
Weighted average by Cap. +1.34%+1.19%+54.08%+170.07%

Financials

2026 *2027 *
Net sales 38.46M 33.63M 31.02M 28.52M 54.03M 3.7B 54.95M 370M 145M 1.81B 144M 141M 6.23B 41.67K 36.43K 33.61K 30.89K 58.54K 4.01M 59.54K 401K 157K 1.96M 156K 153K 6.75M
Net income -288M -251M -232M -213M -404M -27.67B -411M -2.77B -1.09B -13.53B -1.08B -1.06B -46.62B -423M -370M -341M -314M -594M -40.72B -605M -4.07B -1.6B -19.9B -1.59B -1.55B -68.59B
Net Debt -1.07B -938M -865M -795M -1.51B -103B -1.53B -10.33B -4.05B -50.46B -4.03B -3.94B -174B -740M -647M -597M -548M -1.04B -71.17B -1.06B -7.12B -2.79B -34.79B -2.78B -2.72B -120B
Logo Structure Therapeutics Inc.
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
Employees
233
Date Price Change Volume
26-07-15 US$49.62 -1.92% 684,482
26-07-14 US$50.59 -2.03% 565,872
26-07-13 US$51.64 -3.22% 490,987
26-07-10 US$53.36 -3.23% 736,852
26-07-09 US$55.14 +0.46% 459,919
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
49.62USD
Average target price
104.59USD
Spread / Average Target
+110.79%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GPCR Stock